Mirna Therapeutics Inc. (MIRN) Given Consensus Recommendation of “Hold” by Brokerages
Mirna Therapeutics Inc. (NASDAQ:MIRN) has received a consensus rating of “Hold” from the six brokerages that are presently covering the firm. Five equities research analysts have rated the stock with a hold recommendation and one has issued a buy recommendation on the company. The average 12-month price objective among brokers that have issued a report on the stock in the last year is $2.05.
MIRN has been the topic of a number of recent research reports. Zacks Investment Research downgraded Mirna Therapeutics from a “buy” rating to a “hold” rating in a research report on Thursday, August 18th. Citigroup Inc. downgraded Mirna Therapeutics from a “buy” rating to a “neutral” rating and lowered their price target for the stock from $7.00 to $4.50 in a report on Tuesday, August 16th. Cantor Fitzgerald downgraded Mirna Therapeutics from a “buy” rating to a “hold” rating and lowered their price target for the stock from $14.00 to $2.00 in a report on Wednesday, September 21st. HC Wainwright initiated coverage on Mirna Therapeutics in a report on Monday, September 12th. They issued a “buy” rating and a $6.00 price target for the company. Finally, Leerink Swann reissued a “neutral” rating and issued a $1.50 price target (down previously from $4.00) on shares of Mirna Therapeutics in a report on Wednesday, September 21st.
Mirna Therapeutics (NASDAQ:MIRN) traded down 4.06% during midday trading on Monday, reaching $1.66. 4,144 shares of the company traded hands. The firm has a 50-day moving average of $2.20 and a 200-day moving average of $3.78. Mirna Therapeutics has a 1-year low of $1.66 and a 1-year high of $11.01. The stock’s market capitalization is $34.59 million.
About Mirna Therapeutics
Mirna Therapeutics, Inc is a clinical-stage biopharmaceutical company developing a pipeline of micro ribonucleic acid (RNA)-based oncology therapeutics. The Company is developing mimics of naturally occurring microRNAs that are designed to restore the tumor suppressor activity and aid appropriate anti-tumor immune response.
Receive News & Stock Ratings for Mirna Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mirna Therapeutics Inc. and related stocks with our FREE daily email newsletter.